

House Bill 261 (COMMITTEE SUBSTITUTE)

By: Representatives Parham of the 94th, Stephens of the 123rd, Parrish of the 102nd, Twiggs of the 8th, and Graves of the 106th

A BILL TO BE ENTITLED
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to
2 controlled substances, so as to change the listings of controlled substances and dangerous
3 drugs; to provide for exempt over-the-counter controlled substances; to require certain
4 information to be included on certain prescription drug orders; to permit prescription drug
5 orders to be transmitted by electronic means; to provide for related matters; to provide for
6 an effective date; to repeal conflicting laws; and for other purposes.

7 **BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:**

8 **SECTION 1.**

9 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
10 substances, is amended by adding to Code Section 16-13-21, relating to definitions, new
11 paragraphs (6.1), (6.2), and (12.5) to read as follows:

12 "(6.1) 'Dangerous drug' means any drug, other than a controlled substance, which cannot
13 be dispensed except upon the issuance of a prescription drug order by a practitioner
14 authorized under this chapter.

15 (6.2) 'DEA' means the United States Drug Enforcement Administration."

16 "(12.05) 'FDA' means the United States Food and Drug Administration."

17 **SECTION 2.**

18 Said chapter is further amended by striking paragraphs (5) and (6) of Code Section 16-13-25,
19 relating to Schedule I controlled substances, and inserting in lieu thereof the following:

20 "(5) Any material, compound, mixture, or preparation which contains any quantity of the
21 following substances, their salts, isomers (whether optical, position, or geometrics), and
22 salts of isomers, unless specifically excepted, whenever the existence of these substances,
23 their salts, isomers, and salts of isomers is possible within the specific chemical
24 designation:

1 (A) Gamma hydroxybutyric acid (gamma hydroxy butyrate); provided, however, that
 2 this does not include any amount naturally and normally occurring in the human body;
 3 and

4 (B) Sodium oxybate, when the FDA approved form of this drug is not:

5 (i) In a container labeled in compliance with subsection (a) or (b) of Code Section
 6 26-3-8; and

7 (ii) In the possession of:

8 (I) A registrant permitted to dispense the drug;

9 (II) Any person other than to whom the drug was prescribed; or

10 (III) Any person who attempts to or does unlawfully possess, sell, distribute, or
 11 give this drug to any other person;

12 (6) Notwithstanding the fact that Schedule I substances have no currently accepted
 13 medical use, the General Assembly recognizes certain of these substances which are
 14 currently accepted for certain limited medical uses in treatment in the United States but
 15 have a high potential for abuse. Accordingly, unless specifically excepted or unless listed
 16 in another schedule, any material, compound, mixture, or preparation which contains any
 17 quantity of methaqualone, including its salts, isomers, optical isomers, salts of their
 18 isomers, and salts of these optical isomers, is included in Schedule I;

19 (7) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);

20 (8) 1-(3-Trifluoromethylphenyl) Piperazine (TFMPP);

21 (9) N-Benzylpiperazine (BZP)."

22 SECTION 3.

23 Said chapter is further amended by striking paragraph (8) of Code Section 16-13-27, relating
 24 to Schedule III controlled substances, and inserting in its place the following:

25 "(8) Dronabinol (synthetic) in sesame oil and encapsulated in a U.S. Food and Drug
 26 Administration approved drug product also known as Marinol;

27 (9) Sodium oxybate, when the FDA approved form of this drug is in a container labeled
 28 in compliance with subsection (a) or (b) of Code Section 26-3-8, in the possession of a
 29 registrant permitted to dispense the drug, or in the possession of a person to whom it has
 30 been lawfully prescribed;

31 (10) Buprenorphine."

32 SECTION 4.

33 Said chapter is further amended by striking paragraph (9), designating said paragraph as
 34 reserved, and by adding a new paragraph (30.05) to subsection (a) of Code Section 16-13-28,
 35 relating to Schedule IV controlled substances, to read as follows:

1 "~~(9) Dextropropoxyphene~~ Reserved;"

2 "(30.05) Propoxyphene (including all salts and optical isomers);".

3 **SECTION 5.**

4 Said chapter is further amended by striking paragraph (2) from Code Section 16-13-29,
5 relating to Schedule V controlled substances, and inserting in its place the following:

6 "(2) ~~Buprenorphine~~ Reserved."

7 **SECTION 6.**

8 Said chapter is further amended by adding a new Code Section 16-13-29.2 to read as follows:
9 "16-13-29.2.

10 The Georgia State Board of Pharmacy shall have the authority to exempt and control the
11 sale of Schedule V controlled substances by rule which shall allow the sale of such
12 substances without the need for issuance of a prescription from a medical practitioner and
13 shall require such substances to be sold only in a pharmacy when such substances are sold
14 without a prescription. Such substances shall be known as Exempt Over-the-Counter
15 (OTC) Schedule V Controlled Substances."

16 **SECTION 7.**

17 Said chapter is further amended by striking subsection (b) and paragraph (2) of subsection
18 (d) of Code Section 16-13-41, relating to prescriptions, and inserting in their respective
19 places the following:

20 "(b) When a ~~registered~~ practitioner writes a prescription drug order to cause the dispensing
21 of a Schedule II substance, he or she shall include the name and address of the person for
22 whom it is prescribed, the kind and quantity of such Schedule II controlled substance, the
23 directions for taking, the signature, and the name, address, telephone number, and ~~federal~~
24 DEA registration number of the prescribing practitioner. Such prescriptions shall be signed
25 and dated by the prescribing practitioner on the date when issued, and the nature of such
26 signatures shall be defined in regulations promulgated by the State Board of Pharmacy.
27 Prescription drug orders for Schedule II controlled substances may be transmitted via
28 facsimile machine or other electronic means only in accordance with regulations
29 promulgated by the State Board of Pharmacy in accordance with Code Section 26-4-80 or
30 26-4-80.1, or in accordance with DEA regulations at 21 C.F.R. 1306."

31 "(2) When a ~~registered~~ practitioner writes a prescription drug order to cause the
32 dispensing of a Schedule III, IV, or V controlled substance, he or she shall include the
33 name and address of the person for whom it is prescribed, the kind and quantity of such
34 controlled substance, the directions for taking, the signature, and the name, address,

1 telephone number, and federal DEA registration number of the prescribing practitioner.
 2 Such prescriptions shall be signed and dated or may be issued orally by the prescribing
 3 practitioner on the date when issued, and the nature of the signature of the prescriber shall
 4 meet the guidelines set forth in Chapter 4 of Title 26, the regulations promulgated by the
 5 State Board of Pharmacy, or both such guidelines and regulations."

6 **SECTION 8.**

7 Said chapter is further amended by striking from subsection (b) of Code Section 16-13-71,
 8 relating to the list of dangerous drugs, the following paragraphs:

- 9 "(119.05) Butenafine;"
- 10 "(349.7) Reserved;"
- 11 "(529.9) Loratadine;"
- 12 "(623.5) Mometazone;"
- 13 "(752.2) Poractant Alpha;"
- 14 "(1002) Triprolidine;"

15 **SECTION 9.**

16 Said chapter is further amended by adding in the appropriate positions in subsection (b) of
 17 Code Section 16-13-71, relating to the list of dangerous drugs, the following paragraphs:

- 18 "(22.2) Almotriptan;"
- 19 "(50.4) Anakinra;"
- 20 "(68.15) Atomoxetine;"
- 21 "(98.2) Bimatoprost;"
- 22 "(102.5) Bivalirudin;"
- 23 "(105.5) Bosentan;"
- 24 "(105.7) Botulinum toxin (B);"
- 25 "(119.05) Butenafine — See exceptions;"
- 26 "(146.6) Caspofungin;"
- 27 "(151.45) Cefditoren;"
- 28 "(240.5) Darbepoetin alfa;"
- 29 "(251.5) Desloratadine;"
- 30 "(293.5) Dimyristoyl;"
- 31 "(325.3) Drospirenone;"
- 32 "(325.4) Drotrecogin alfa;"
- 33 "(325.5) Dutasteride;"
- 34 "(346.5) Ertapenem;"
- 35 "(349.7) Esomeprazole;"

- 1 "(404.7) Fondaparinux;"
 2 "(406.2) Formoterol;"
 3 "(406.95) Frovatriptan;"
 4 "(408.9) Galantamine;"
 5 "(464.8) Imatinib;"
 6 "(474.2) Insulin aspart;"
 7 "(513.8) Letrozole;"
 8 "(529.9) Loratadine — See exceptions;"
 9 "(623.5) Mometasone;"
 10 "(625.3) Moxidectin;"
 11 "(640.2) Nesiritide;"
 12 "(644.8) Nitisinone;"
 13 "(703.45) Perflexane;"
 14 "(703.65) Perflutren;"
 15 "(732.9) Pimecrolimus;"
 16 "(752.2) Poractant alfa;"
 17 "(930.9) Tadalafil;"
 18 "(931.55) Tegaserod;"
 19 "(931.85) Tenofovir;"
 20 "(932.3) Teriparatide;"
 21 "(974.4) Travoprost;"
 22 "(974.7) Treprostinil;"
 23 "(1002) Triprolidine — See exceptions;"
 24 "(1021.8) Valdecoxib;"
 25 "(1022.2) Valganciclovir;"
 26 "(1037.5) Voriconazole;"
 27 "(1042.75) Ziprasidone;"
 28 "(1042.8) Zoledronic Acid;".

29 **SECTION 10.**

30 Said chapter is further amended by striking from subsection (c) of Code Section 16-13-71,
 31 relating to the list of dangerous drugs, the following paragraphs:

- 32 "(12) Insulin, All;"
 33 "(14.1) Miconazole — when used as antifungal powder, cream, or both, and containing
 34 not more than 4 percent of miconazole nitrate, and when used as a vaginal insert of up to
 35 200 mg. in strength;".

SECTION 11.

Said chapter is further amended by adding in the appropriate positions in subsection (c) of Code Section 16-13-71, relating to the list of dangerous drugs, the following paragraphs:

"(6.2) Butenafine — when used with a strength of 1 percent or less as a topical preparation;"

"(12) Insulin — all injectable products which do not require a prescription drug order and bear a label which indicates 'Rx Use Only' or are otherwise listed under subsection (b) of this Code section; and no injectable insulin product may be sold except by a pharmacy issued a permit by the State Board of Pharmacy or by a medical practitioner authorized to dispense medications;"

"(13.7) Loratadine — when used in a single dose of 10 mg. or less, including doses used in combination with other drugs provided for under this subsection;"

"(14.1) Miconazole — when used as antifungal powder or cream, or both, and containing not more than 4 percent of miconazole, or when used as a vaginal insert and containing not more than 1,200 mg. of miconazole;"

"(28.5) Triprolidine — when a single dose is 5 mg. or less when combined in the same preparation as one or more other drug products for use as an antihistamine or decongestant or an antihistamine and decongestant;"

SECTION 12.

Said chapter is further amended by striking subsection (a) of Code Section 16-13-74, relating to written prescriptions for dangerous drugs, content, and signature, and inserting in its place the following:

"(a) All written ~~prescriptions~~ prescription drug orders for dangerous drugs shall be dated as of, and be signed on, the date when issued and shall bear the full name and address of the patient, together with the name and strength of the drug, the quantity to be dispensed, complete directions for administration, the printed name, address, and telephone number of the practitioner, and the number of permitted refills. ~~A practitioner may sign a prescription as he would sign a check or a legal document. The prescription shall be written with indelible pencil or indelible ink or typewritten and shall be manually signed by the practitioner. The prescription may be prepared by a secretary or other agent, for the signature of the practitioner, but the prescribing practitioner shall be responsible if the prescription does not conform in all essential respects to state and federal laws and regulations. A prescription drug order for a dangerous drug is not required to bear the DEA permit number of the prescribing practitioner. A prescription drug order for a dangerous drug may be prepared by the practitioner or the practitioner's agent. The practitioner's signature must appear on each prescription prepared by the practitioner or the practitioner's~~

1 agent and the nature of the practitioner's signature must meet the guidelines set forth in
2 Chapter 4 of Title 26, the regulations promulgated by the State Board of Pharmacy, or both
3 such guidelines and regulations. Any practitioner who shall dispense dangerous drugs shall
4 comply with the provisions of Code Section 16-13-73."

5 **SECTION 13.**

6 This Act shall become effective upon its approval by the Governor or upon its becoming law
7 without such approval.

8 **SECTION 14.**

9 All laws and parts of laws in conflict with this Act are repealed.